Sunday, March 17, 2013
Australia - Hormones Can Change DNA In Breast Cells, Study
Scientists in Australia have discovered how female steroid hormones can make dramatic changes to the genetic material in breast cells.
Scientists in Australia have discovered how female steroid hormones can make dramatic changes to the genetic material in breast cells, changes that could potentially lead to breast cancer.
The study, published recently in the journal Cell Reports, was conducted by researchers from the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia.
Here, they created a roadmap of the epigenomes of different breast cell types, and determined how the epigenomes changed in response to ovarian hormones such as progesterone. The epigenome is a series of chemical tags that modify DNA, controlling which genes are switched on and off.
“We found the epigenome was very sensitive to hormonal regulation,” said Professor Jane Visvader, a senior author on the study. “This reveals another way in which female hormones can influence breast cancer risk – by altering the epigenome through modifications in DNA tags.”
The epigenome is where the DNA and the environment intersect, communicating signals from the outside world to the DNA. The epigenome doesn’t alter the genetic code, but is a layer of proteins that sits ‘on top’ of the DNA and provides instructions on whether DNA should be read and ‘switched on’ to produce proteins.
The research team found that pregnancy hormones activate a molecule called EZH2, which is an important modifier of the epigenome.
“We found that hormones including progesterone activate EZH2 to modify the epigenome, leading to global changes in the expression of a huge number of genes,” Visvader said.
“In normal tissue, EZH2 is essential for the development of breast tissue including ducts and milk-producing cells, and for maintaining the activity of breast stem cells and their daughter progenitor cells.
However, life-long exposure to hormones could lead to breast tumor initiation through increased levels of EZH2 and the changes that it orchestrates in the epigenome,” she explained.
Breast cancer is the most common cause of cancer in women, accounting for almost 30 percent of all cancers affecting women. High levels of EZH2 are a marker of poor prognosis in breast cancer and have been frequently observed in basal-like breast cancers, the most aggressive types of breast cancer.
“The link between progesterone, EZH2 and the epigenome, could be crucially important in the very early stages of breast cancer development,” she said.
Professor Geoff Lindeman, another senior author on the study, said there were decades of evidence linking hormone exposure with breast cancer, but the hormones’ influence on the epigenome was not known.
“Our discovery points to a role for hormone-induced changes in the epigenome in the early stages of breast cancer initiation, and could lead to new therapeutics for treating breast cancer,” Lindeman said.
“Inhibitors against EZH2 are being developed by others, but it will be several years before we know the outcome of these on cancer.”
The article can be found at: Pal B et al. (2013) Global Changes in the Mammary Epigenome Are Induced by Hormonal Cues and Coordinated by Ezh2.